Progress with Purpose
Half-Year Financial Report 2026
Letter from the CEO
Read full CEO LetterThe first half of 2026 marked the beginning of a new chapter for our company. We became Lakefront Biotherapeutics, a name that reflects both the strategic direction we have set and the company we are building. It aligns our identity with our focus.
A conversation with Henry and Gino
Read full conversationWe sat down with our CEO, Henry Gosebruch, and Board Chair, Gino Santini, to discuss the company’s first six months of 2026, the strategic significance of the Ouro transaction, the evolution of Lakefront’s pipeline and the priorities for the remainder of the year.
